SCHEMBL19629035

SCHEMBL19629035

CCCCCCCCCCCCCCCCCCCC(=O)CC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.65
MAPT P10636 1/20 0.65
CES2 O00748 4/20 0.62
CES1 P23141 4/20 0.62
GPR84 Q9NQS5 7/20 0.59
PPARG P37231 7/20 0.59
PPARD Q03181 7/20 0.59
PPARA Q07869 7/20 0.59
HDAC11 Q96DB2 5/20 0.59
TSHR P16473 4/20 0.59
PTPN1 P18031 3/20 0.59
ALDH1A1 P00352 2/20 0.59
TLR2 O60603 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
FABP4 P15090 2/20 0.59
SLC22A6 Q4U2R8 1/20 0.59
SLC22A8 Q8TCC7 1/20 0.59
MEN1 O00255 1/20 0.59
ESR1 P03372 1/20 0.59
ALOX15 P16050 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2782616 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL6840834 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL888107 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL105548 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL811181 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL632531 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL1153187 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL21044695 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL21044630 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84
SCHEMBL966153 1.00 KMT2A (0.65) KMT2AMAPTCES2CES1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198200-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS ARES CAPITAL CORPORATION, AS AGENT 2021-07-01 US disclosed
WO-2021055833-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2021-03-25 WO disclosed
US-10544154-B2 Opioid receptor antagonist prodrugs NIRSUM LABORATORIES, INC. (US) 2020-01-28 US disclosed
CN-105121542-B Vinyl chloride resin composition for transparent products 株式会社ADEKA 2018-01-12 CN disclosed
WO-2017201328-A1 POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE MODERNATX, INC. (US) 2017-11-23 WO disclosed
CN-107250256-A Vinyl chloride resin composition 株式会社艾迪科 2017-10-13 CN disclosed
CN-104704044-B Resin composition for printed film and printed film 株式会社ADEKA 2017-04-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198200-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS LNPK, PLTP, PHOSPHO1 KMT2A 4301/4885MAPT 2543/4885CES2 2229/4885
US-10544154-B2 Opioid receptor antagonist prodrugs OPRM1, OPRK1, OPRL1 KMT2A 672/4885MAPT 1208/4885CES2 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.